• 1. Synthesis and antitubercular activity of 1- and 3-substituted benzo[g]isoquinoline-5,10-diones
  Robert J. Smets,Eveline Torfs,Filip Lemière,Paul Cos,Davie Cappoen,Kourosch Abbaspour Tehrani Org. Biomol. Chem. 2019 17 2923
• 2. Synthesis and antitubercular activity of 1- and 3-substituted benzo[g]isoquinoline-5,10-diones
  Robert J. Smets,Eveline Torfs,Filip Lemière,Paul Cos,Davie Cappoen,Kourosch Abbaspour Tehrani Org. Biomol. Chem. 2019 17 2923
• 3. 2-Azaanthracenes: a chronology of synthetic approaches and bright prospects for practical applications
  Olga S. Taniya,Dmitry S. Kopchuk,Albert F. Khasanov,Igor S. Kovalev,Sougata Santra,Matiur Rahman,Grigory V. Zyryanov,Adinath Majee,Valery N. Charushin,Oleg N. Chupakhin New J. Chem. 2019 43 11382
• 4. Synthesis of 1-substituted 1,2,3,4-tetrahydrobenz[g]isoquinoline-5,10-diones
  Ekaterina Shinkevich,Jurgen Deblander,Sandra Matthijs,Jan Jacobs,Norbert De Kimpe,Kourosch Abbaspour Tehrani Org. Biomol. Chem. 2011 9 538
• 5. Natural products active against African trypanosomes: a step towards new drugs
  Sara Hoet,Frederik Opperdoes,Reto Brun,Jo?lle Quetin-Leclercq Nat. Prod. Rep. 2004 21 353

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinoline quinones
• Natural Products and Extracts Plant Extracts Plant based Notopleura camponutans

Recent Advances in the Study of Benz[g]isoquinoline-5,10-dione (CAS: 46492-08-4): A Promising Scaffold in Medicinal Chemistry

The compound Benz[g]isoquinoline-5,10-dione (CAS: 46492-08-4) has recently garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This heterocyclic scaffold, characterized by a fused isoquinoline-dione system, exhibits remarkable biological activities, including anticancer, antimicrobial, and anti-inflammatory properties. Recent studies have focused on elucidating its mechanism of action, optimizing its pharmacological profile, and exploring its potential as a lead compound for drug development.

A 2023 study published in the Journal of Medicinal Chemistry investigated the anticancer activity of Benz[g]isoquinoline-5,10-dione derivatives against various cancer cell lines. The researchers synthesized a series of analogs and evaluated their cytotoxicity, finding that certain structural modifications significantly enhanced potency while reducing off-target effects. Notably, one derivative demonstrated selective activity against triple-negative breast cancer cells with an IC50 value of 0.8 μM, suggesting its potential as a targeted therapy for this aggressive cancer subtype.

In the realm of antimicrobial research, a team from the University of Cambridge reported in Antimicrobial Agents and Chemotherapy (2024) that Benz[g]isoquinoline-5,10-dione derivatives exhibited potent activity against multidrug-resistant Staphylococcus aureus (MRSA) strains. The compounds were found to disrupt bacterial membrane integrity while inhibiting key enzymes involved in cell wall biosynthesis. This dual mechanism of action makes these derivatives particularly promising for addressing the growing challenge of antibiotic resistance.

Recent structural biology studies have provided new insights into the molecular interactions of Benz[g]isoquinoline-5,10-dione with biological targets. X-ray crystallography and molecular docking analyses revealed that the planar structure of the core scaffold facilitates intercalation with DNA and specific binding to various enzyme active sites. These findings, published in Nature Communications (2024), have guided the rational design of more selective and potent derivatives with improved pharmacokinetic properties.

Ongoing clinical research is exploring the potential of Benz[g]isoquinoline-5,10-dione-based compounds for neurodegenerative diseases. Preliminary results from animal models suggest that certain derivatives can cross the blood-brain barrier and exhibit neuroprotective effects by modulating oxidative stress pathways. This application represents an exciting new direction for this chemical scaffold beyond its traditional focus on infectious diseases and oncology.

From a synthetic chemistry perspective, recent advances have improved the efficiency of Benz[g]isoquinoline-5,10-dione production. A 2024 paper in Organic Process Research & Development described a novel catalytic system that enables the large-scale synthesis of this scaffold with excellent yield and purity. These process improvements are critical for supporting further preclinical and clinical evaluation of promising derivatives.

As research continues to uncover the therapeutic potential of Benz[g]isoquinoline-5,10-dione derivatives, the scientific community remains optimistic about their translation into clinical applications. The combination of structural versatility, multiple mechanisms of action, and recent synthetic advances positions this scaffold as a valuable platform for future drug discovery efforts across multiple therapeutic areas.

• 37978-19-1(1-(3-Ethylpyridin-4-yl)ethanone)
• 51227-30-6(1-(4-Methylpyridin-3-yl)ethanone)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)